This narrative review aims to discuss current evidence about the role of the recently FDA-approved SGLT-2 inhibitor bexagliflozin as an adjunct therapy to diet and exercise to improve glycaemic control in adults with T2D. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.